Pelago Bioscience and Vertex Pharmaceuticals have entered into a 2-year strategic research collaboration and license agreement.
During the collaboration, the companies will together develop assay expertise in all CETSA formats and will also generate data to determine the value of implementing CETSA widely across Vertex’s drug discovery pipeline.
“This collaboration will allow us to explore the value of CETSA in screening, translation and safety pharmacology in collaboration with the scientists at Vertex,” says Michael Dabrowski, CEO of Pelago Bioscience.
